{"id":"del-desiran-aoc-1001","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Transient liver enzyme elevation"},{"rate":null,"effect":"Flu-like symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Del-desiran binds to apoC-III mRNA in hepatocytes, triggering degradation of the transcript and reducing circulating apoC-III levels. ApoC-III inhibits lipoprotein lipase and is associated with elevated triglycerides and cardiovascular risk; lowering it improves triglyceride clearance and lipid profiles.","oneSentence":"Del-desiran is an antisense oligonucleotide that reduces production of apolipoprotein C-III (apoC-III) to lower triglycerides and improve lipid metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:56.141Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertriglyceridemia"},{"name":"Cardiovascular risk reduction in patients with elevated triglycerides"}]},"trialDetails":[{"nctId":"NCT07008469","phase":"PHASE3","title":"Global Open-Label Extension Study of Del-desiran for the Treatment of DM1","status":"ENROLLING_BY_INVITATION","sponsor":"Avidity Biosciences, Inc.","startDate":"2025-07-25","conditions":"Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy","enrollment":230},{"nctId":"NCT06411288","phase":"PHASE3","title":"Global Study of Del-desiran for the Treatment of DM1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Avidity Biosciences, Inc.","startDate":"2024-05-30","conditions":"DM1, Myotonic Dystrophy, Myotonic Dystrophy 1","enrollment":159}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Del-desiran (AOC 1001)","genericName":"Del-desiran (AOC 1001)","companyName":"Avidity Biosciences, Inc.","companyId":"avidity-biosciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Del-desiran is an antisense oligonucleotide that reduces production of apolipoprotein C-III (apoC-III) to lower triglycerides and improve lipid metabolism. Used for Hypertriglyceridemia, Cardiovascular risk reduction in patients with elevated triglycerides.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}